Hut 8 (NASDAQ:HUT – Get Free Report) and Avalon GloboCare (NASDAQ:CHGA – Get Free Report) are both technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.
Earnings & Valuation
This table compares Hut 8 and Avalon GloboCare”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hut 8 | $235.12 million | 36.19 | -$226.15 million | ($5.45) | -12.67 |
| Avalon GloboCare | $1.26 million | 1.24 | -$18.26 million | ($13.80) | -0.10 |
Avalon GloboCare has lower revenue, but higher earnings than Hut 8. Hut 8 is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Hut 8 and Avalon GloboCare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hut 8 | 1 | 1 | 18 | 4 | 3.04 |
| Avalon GloboCare | 1 | 0 | 0 | 0 | 1.00 |
Hut 8 presently has a consensus target price of $148.09, suggesting a potential upside of 114.50%. Given Hut 8’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Hut 8 is more favorable than Avalon GloboCare.
Insider and Institutional Ownership
31.8% of Hut 8 shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 10.4% of Hut 8 shares are owned by insiders. Comparatively, 16.8% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Hut 8 has a beta of 4.62, suggesting that its stock price is 362% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500.
Profitability
This table compares Hut 8 and Avalon GloboCare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hut 8 | -188.59% | -0.97% | -0.36% |
| Avalon GloboCare | N/A | N/A | -53.69% |
Summary
Hut 8 beats Avalon GloboCare on 10 of the 14 factors compared between the two stocks.
About Hut 8
Hut 8 Corp., together with its subsidiaries, acquires, builds, manages, and operates data centers for digital assets mining, computing, and artificial intelligence in the United States. It operates in four segments: Digital Assets Mining, Managed Services, High Performance Computing Colocation and Cloud, and Other. The company mines Bitcoin. It also offers managed services for energy infrastructure development, such as site design, procurement, and construction management; software automation, process design, personnel hiring, and team training; utilities contracts, hosting operations, and customer management; energy portfolio optimization and strategic initiatives; and finance, accounting, and safety services for digital asset mining site owners, governments, and data center developers. In addition, the company provides colocation, cloud, and connectivity services; hosting services, which include the provision of mining equipment and space, as well as monitors, troubleshoots, repairs, and maintains customer mining equipment; and equipment sales and repair services. Hut 8 Corp. was founded in 2017 and is based in Miami, Florida.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Receive News & Ratings for Hut 8 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hut 8 and related companies with MarketBeat.com's FREE daily email newsletter.
